tocilizumab + propofol + phenobarbital + midazolam

This is a non-standard, multi-drug combination consisting of four agents with distinct mechanisms and clinical uses: - **Tocilizumab** is a monoclonal antibody that acts as an interleukin-6 (IL-6) receptor antagonist, primarily used for autoimmune conditions such as rheumatoid arthritis and cytokine release syndrome. - **Propofol** is a short-acting intravenous anesthetic agent used for induction and maintenance of general anesthesia or sedation. It acts mainly by potentiating GABA-A receptor activity. - **Phenobarbital** is a long-acting barbiturate with anticonvulsant and sedative properties, acting as an allosteric modulator of the GABA-A receptor to enhance inhibitory neurotransmission. - **Midazolam** is a short-acting benzodiazepine used for sedation, anxiolysis, amnesia, and seizure control. It also enhances GABAergic transmission at the GABA-A receptor. There are no known approved pharmaceutical products or clinical guidelines recommending the simultaneous use of all four drugs together. However, combinations involving propofol, phenobarbital, and midazolam are sometimes considered in critical care settings (e.g., refractory status epilepticus or deep sedation), but not typically with tocilizumab[1][2][3][4][5][6]. The pharmacological rationale would involve profound immunosuppression (tocilizumab) alongside deep CNS depression from three sedative-hypnotics.

Brand names

Actemra

Other names

tocilizumab + propofol + phenobarbital + midazolam